左氧氟沙星治疗耐多药肺结核临床疗效分析

目的:评价左氧氟沙星治疗耐多药肺结核临床效果,为临床用药提供基础依据。方法:选取2011年7月至2013年6月在信阳市第五人民医院治疗的耐多药肺结核患者136例,按照患者就诊号奇偶性随机分为治疗组和对照组,每组68例,治疗组采用左氧氟沙星,对照组采用氧氟沙星,两组患者均采取相同的抗结核基础联合用药,治疗2个疗程后对两组患者治疗效果进行评价。结果:治疗2个疗程时,治疗组患者痰结核菌阴转率为94.1%,显著高于对照组,差异具有统计学意义(P<0.05);复查X线片,治疗组患者肺结核活动灶吸收率为94.1%,对照组为82.4%,差异具有统计学意义(P<0.05);治疗组不良事件发生率远低于对照组,差异具有统计学意义(P<0.05)。结论:左氧氟沙星治疗耐多药肺结核疗效较佳,且副作用小,值得在临床上推广。

Analysis on the efficacy of levofloxacin in the treatment of multidrug-resistant tuberculosis

Objective ： To investigate the efficacy of levofloxacin in treatment of multidrug-resistant tuberculosis, and provide basis for clinical treatment. Methods： 136 cases of muhidrug-resistant tuberculosis treated in the Fifth People＇ s Hospital of Xinyang were selected from July 2011 to June 2013, randomly divided into treatment group and control group according to the visiting sequence, 68 cases in each group. The treatment group received levofloxacin and the control group received ofloxacin. All the patients took the same basic anti-TB drug combination. After two courses of treatment, the effects of the two groups were evaluated. Results： After two courses of treatment, the sputum negative conversion rate in the treatment group was 94.1% , significantly higher than the control group, the difference was statistically significant （P 〈 0.05）. The absorption rate of tuberculosis active lesions in treatment group and control group were 94.1% and 82.4% respectively, the difference was statistically significant （P 〈 0.05）. The adverse event rate in the treatment group was far lower than the control group （P 〈 0.05 ）. Conclusion ： Levofloxacin tuberculosis had better efficacy and less side effects in the treatment of muhidrug-resistant. It was worthy of clinical application.